Roctavian, Hem A Gene Therapy, Sustains Drop in Bleeding Rates, Fase 3 Data Show

Roctavian, Hem A Gene Therapy, Sustains Drop in Bleeding Rates, Fase 3 Data Show

Notícias sobre hemofilia hoje

Imagem

Please enable the javascript to submit this form

Apoiado por bolsas educacionais da Bayer, BioMarin, Freeline Therapeutics Limited, Pfizer Inc., Shire, Spark Therapeutics e uniQure, Inc.

SSL essencial